Deep Posterior Post Gluteal Compartment Block in Total Hip Arthroplasty: Feasability and Safety

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorQuincy Anesthésie

About this trial

This study aims to evaluate the effectiveness of a posterior hip capsule block performed in addition to a PENG (Pericapsular Nerve Group) block for patients undergoing hip arthroplasty. The primary objective is to assess whether this combined approach provides enhanced perioperative analgesia compared to the standard analgesic protocol or the PENG block alone. Secondary outcomes will focus on opioid consumption, functional recovery, and any potential complications. By targeting both the anterior and posterior innervation pathways around the hip joint, this combined technique could improve patient comfort, decrease opioid requirements, and potentially expedite rehabilitation after hip arthroplasty.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

Contraindication to regional anesthesia

allergy

refusal of the injection

Trial design

Design model

Single group

Treatments tested in this trial

  • Deep posterior post gluteal nerve block

    Procedure/Surgery

    One injection with ultrasound guidance injection of 5, 10 or 15 mL of naropeine 0.35 % Procedure : injection below the piriformis muscle in front of the head of the femur.

Treatment groups

35 Participants
are divided into 1 treatment group
Group A: DPPG compartment blockExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Sciatic nerve block

number of patients with postoperative sciatic motor or sensitory nerve block collected by clinical examination (test with hot and cold in the sciatic territory and motricity of the feet)

Time frame
From enrollment to the end of treatment at 1 month

Secondary outcomes

1

Pain postoperative

Visual analogic pain (VAS) AT 6 hours 0 : no pain 10: maximum pain

Time frame
From enrollment to the end of treatment at 1 MONTH
2

pain 2

Visual analogic pain (VAS) AT 12 hours 0 : no pain 10: maximum pain

Time frame
From enrollment to the end of treatment at 1 MONTH
3

oPIOID Consumption

Opioid consumption per and postoperative until 48 hours

Time frame
From enrollment to the end of treatment at 7 months
4

RAAC

QOR15 scale at H24 and H48 questionnaire with 15 questions from 0 to 10 (https://pqip.org.uk/FilesUploaded/Myles%20QoR-15.pdf)

Time frame
From enrollment to the end of treatment at 1 MONTH

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: